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Abstract
Responsive polymeric biomaterials can be triggered to degrade using localized environments
found in vivo. A limited number of biomaterials provide precise control over the rate of
degradation, the release rate of entrapped cargo, and yield a material that is intrinsically non-toxic.
Here we design non-toxic acid-sensitive biomaterials based on silyl ether chemistry. A host of
silyl ether cross-linkers were synthesized and molded into relevant medical devices including
Trojan horse particles, sutures, and stents. The resulting devices were engineered to degrade under
acidic conditions known to exist in tumor tissue, inflammatory tissue, and within diseased cells.
The implementation of silyl ether chemistry gave precise control over the rate of degradation, and
depending upon the steric bulk around the silicon atom, afforded devices that could degrade over
the course of hours, days, weeks, or months. These novel materials could be useful for numerous
biomedical applications including drug-delivery, tissue repair, and general surgery.
Introduction
Silyl ethers are one of the most widely used protecting groups in organic chemistry.1 Their
popularity can be attributed to their ability to modulate the rate of deprotection depending
upon the substituents on the silicon atom. For instance, trimethyl silyl ether (TMS), triethyl
silyl ether (TES), and triisopropyl silyl ether (TIPS) protecting groups have a relative
stability to acid catalyzed hydrolysis of 1, 64, and 700,000 respectively.1 By simply
changing the substituents from methyl to ethyl to isopropyl one can alter the rate of
deprotection by orders of magnitude. Additionally, silyl ethers provide precise control over
the rate of deprotection, the mechanism of deprotection, and the overall stability of a
material. This class of chemistries has remained relatively unnoticed outside of protecting
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group strategies. A successful adaptation of silyl ether chemistry, however, would afford a
wide range of materials programmed to degrade under specific conditions found in vivo.
Researchers have exploited in vivo reducing environments,2–4 enzymes,5–7 and pH
gradients8–10 to trigger the cleavage or degradation of biomaterials. Specifically,
hydrazones,11 trityls,12 aconityls,13 vinyl ethers,14 poly(ketals),15,16 acetals,17 poly(ortho
esters),18 and thiopropionates19 utilize naturally occurring pH gradients to catalyze
degradation, but are limited by tunability, toxic byproducts, or meticulous, multi-step
syntheses. Conversely, a silyl ether linkage can be formed in one simple step, the
degradation byproducts are non-toxic, and the linkage can be designed to degrade at
different rates by merely altering the substituent on the silicon atom.
One silyl ether linkage of interest is the bifunctional silyl ether (BSE). Bifunctional silyl
ethers consist of a C-O-Si(R)2-O-C linkage, and are commonly used for the protection of 1,2
and 1,3 diols.20–22 The less hindered dimethyl, diethyl and diisopropyl BSEs are
exceedingly susceptible to acid catalyzed hydrolysis, and are typically avoided as protecting
groups. Although this property is unfavorable for protection strategies, less-hindered BSEs
provide the ideal characteristics for highly susceptible, acid sensitive biomaterials.
Results and Discussion
We therefore set out to prepare a collection of BSE cross-linkers with a variety of
substituents on the silicon atom. The production of the desired cross-linkers utilized
commercially available starting materials and required only one synthetic step, which
proved to be inexpensive, rapid, and facile. Two similar silyl ether reactions (Scheme 1A
and 1B) provided four novel, photopolymerizable cross-linkers denoted as 1, 2, 3 and 4. For
simplicity, we refer to the different cross-linkers according to the substituents on the silicon
atom. For example, the cross-linker with two methyl substituents is referred to as dimethyl
silyl ether or DMS, and the cross-linker with two ethyl substituents is referred to as diethyl
silyl ether or DES.
Each cross-linker was molded into “Trojan horse” microparticles using a particle fabrication
process called Particle Replication In Non-wetting Templates (PRINT).23 PRINT is a top-
down approach used to manufacture microparticles24–26 and nanoparticles27–29 with well
defined size and shape. Two particle shapes were fabricated, 5 μm cube particles (Figure 1A
and 1B), and 3 μm hexnut particles (Figure 2C and 2D) (full particle characterization can be
seen in the supporting information). The microparticles were successfully prepared with
each BSE cross-linker and were degraded under acidic conditions known to exist inside
various cellular compartments.9 The larger 5 μm cube particles were employed to determine
the rate of particle degradation at simulated lysosomal, endosomal, and physiological pH, or
pH 5.0, 6.0, and 7.4 respectively.9 A quantitative analysis of particle degradation was carried
out on particles fabricated from DMS (1), DES (2), and DIS (3) cross-linkers, and loaded
with 2 weight percent rhodamine-B. The particles were degraded and aliquots of the
supernatant were removed, filtered, and the concentration of rhodamine-B was measured
using UV spectroscopy. For accuracy, this experiment was repeated three times and the
average data was fit to an exponential growth model to determine degradation half-lives.
A plot of rhodamine-B release versus time for particles fabricated with the DMS cross-linker
(Figure 2A) displayed an accelerated rate of degradation when dispersed in a medium
buffered at pH 5.0, and exhibited a degradation half life of 0.091 days or 2.19 hours (Table
1). The same particles dispersed in a medium buffered at pH 6.0 had a half live of 1.08 days,
and particles dispersed in a medium buffered at pH 7.4 had a half live of 2.94 days. From
this data it was apparent that the particles fabricated from the DMS cross-linker
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preferentially degraded under acidic conditions, and the rate of degradation was accelerated
as the pH decreased. Using identical conditions, particles fabricated with the DES cross-
linker also degraded preferentially under acidic conditions (Figure 2B), but the rate of
degradation was noticeably different. The DES particles appeared to degrade 13.6 times
slower than the DMS particles when dispersed in a medium buffered at pH 5.0, and
approximately 10 times slower when degraded in a medium buffered at pH 6.0 or pH 7.4.
Furthermore, the rate of degradation of particles fabricated with the DIS cross-linker (Figure
2C) was slower by 2 orders of magnitude for all pH levels. This illustrates that by simply
changing the substituent around the silicon atom one can effectively modulate the rate of
particle degradation from hours to days to weeks to months.
Intracellular degradation of silyl ether PRINT particles could be visualized using
transmission electron microscopy (TEM) and laser scanning confocal microscopy. We
selected the hexnut shaped particles for this experiment due to their unique shape, which
makes them easily distinguishable from cellular compartments. Two separate batches of
hexnut particles were fabricated, one from the rapidly degrading DMS cross-linker, and one
from the non degrading DTS cross-linker. A small amount of positively charged N-(3-
aminopropyl)methacrylamide hydrochloride (APMA-HCl) was added to the composition to
ensure a positive zeta potential and cellular internalization.30 The transmission electron
micrographs were captured in bright-field mode, which allows less dense material to appear
white and highly dense material to appear dark.31 Particles fabricated with the rapidly
degrading DMS cross-linker can be seen in Figure 3A, where one DMS-hexnut particle was
internalized, and three DMS-hexnut particles remain outside of the HeLa cell. A closer look
of the internalized particle (Figure 3B) showed a bright white mass resembling a hexnut
particle. The bright white color signifies that the particle became less dense than the
surrounding intracellular matrix, and significantly less dense than the same particles found
outside of the cell. The non-internalized DMS-hexnut particles (Figure 3C) appeared to be
completely intact, and the size and shape of the particles were found to be equivalent to the
size and shape of the particles imaged by scanning electron microscopy. Additional
micrographs were taken to monitor the course of the DMS-hexnut degradation, and the
internalized hexnut particles always became less dense or bright white, they appeared to
swell (Figure 3D), then fragment (Figure 3E), and finally undergo surface erosion (Figure
3F). Particles prepared with the non-degrading DTS cross-linker can be seen in Figures 3G
and 3H. These particles were also internalized within HeLa cells (and hence exposed to an
acidic environment) but due to the stability of the cross-linker, the particle was not
susceptible to degradation. In addition, there was no noticeable change to the shape, size, or
density of the DTS-hexnut particles internalized inside HeLa cells.
Further investigation of intracellular degradation of silyl ether particles was achieved
utilizing laser confocal microscopy. Two particle types were fabricated; one containing the
rapidly degrading DMS cross-linker with fluorescein-o-acrylate (green fluorescent dye), and
another particle containing the non-degrading DTS cross-linker and methacryloxyethyl
thiocarbamoyl rhodamine-B (red fluorescent dye). HeLa cells were incubated for 24 h with
both the rapidly degrading particles (green) and the non-degrading particles (red) (Figure 4).
It was clear that after cellular internalization the non-degrading DTS particles appeared to
maintain the same size and shape and were not altered by intercellular conditions. On the
other hand, the degradable DMS particles exhibited a number of different characteristic
including; enlargement or swelling, loss of the distinct hexnut shape, fragmentation, and
complete degradation as illustrated by the diffuse green fluorescence found in Figure 4C.
Cell viability experiments were performed to determine if the degradation byproducts were
toxic. This was accomplished by separately dosing all four silyl-ether hexnut-particles
(DMS, DES, DIS, and DTS) onto both HeLa and SKOV3 cell lines. The cytotoxicity of each
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particle was determined using the CellTiter-Glo® luminescent cell viability assay (Figure 5).
All of the silyl ether PRINT particles dosed onto HeLa and SKOV3 cells showed minimal
toxicity across a large concentration range. These assays suggested that the silyl ether
chemistry is non-toxic and the degradation byproducts appeared to be well tolerated in cells.
The novelty of bifunctional silyl ether cross-linkers is not limited to particle-based drug
delivery applications. Devices fabricated from silyl ether biomaterials could also be useful
for tissue repair, and general surgery. Biodegradable, and bioabsorbable devices are
routinely used in hospitals and are often made from a co-polymer of lactic acid and glycolic
acid identified as poly(lactic-co-glycolic acid) or PLGA.32 A device made from PLGA is
susceptible to both acid catalyzed degradation and enzymatic degradation by esterases.33–35
Due to variable levels of enzymes, PLGA can degrade at different rates in different
patients.36 To the best of our knowledge, an enzyme specific to the silyl ether linkage does
not exist. Therefore, devices fabricated from silyl ether biomaterials should only be
susceptible to an acid catalyzed mechanism, and consequently minimize patient to patient
variability.
Rudimentary medical devices such as sutures and stents were manufactured from the silyl
ether cross-linkers according to several different procedures. As shown in Figure 6A, a thin
fiber of the DMS cross-linker was prepared with a small amount of rhodamine-B. The fiber
was designed with a diameter of 0.3 mm and a length of 50 cm, and would be recognized as
a class 2-0 USP suture. The fiber was cut and placed in media buffered at pH 5.0 and pH
7.4. Analogous to the PRINT particles, the rate of degradation of the DMS fiber was
accelerated at pH 5.0. Furthermore, the fiber suspended in medium buffered at pH 7.4
remained unbroken and showed minimal release of the rhodamine-B cargo over the course
of 4 hours.
Stent-like devices were also made using each silyl ether cross-linker (Figure 6B). Each stent
had an outer diameter of 3 mm, an inner diameter of 2.5 mm, a thickness of 0.25 mm, and a
length of 25 mm, analogous to the dimensions of a typical coronary stent. Each stent was
placed in an acidic solution (pH 5.0) and allowed to degrade over the course of 3 days. After
the experiment was completed the stent made from the rapidly degrading DMS cross-linker
showed significant change in shape and morphology. The stent made from the DES cross-
linker became swollen and opaque, indicating the onset of degradation, while the remaining
DIS and DTS stents showed no change over the course of the experiment.
Conclusions
Bifunctional silyl ether cross-linkers were investigated as a new biomedical material useful
for drug delivery and degradable devices. Using one facile synthetic step, we were able to
synthesize four cross-linkers from commercially available reagents. Each cross-linker was
successfully integrated into the PRINT platform, and yielded Trojan horse particles for drug-
delivery. The particles were degraded under 3 different pH environments and the rate of
degradation was accelerated as the pH decreased. Interestingly, the rate of acid catalyzed
hydrolysis could be altered by orders of magnitude by simply changing the substituents on
the silicon atom. In vitro particle degradation was visualized using transmission electron
microscopy and laser confocal spectroscopy, which highlighted preferential degradation of
particles internalized inside cells. Preliminary in vitro cytotoxicity data suggested that these
materials were well tolerated across a large concentration range in two cell lines.
Furthermore, the silyl ether biomaterials were molded into two practical medical devices,
and shown to preferentially degrade under reduced pH. The rational design and
implementation of silyl ether chemistry provided a fast and simple approach to a host of acid
sensitive biomaterials. Further development of this silyl ether chemistry could generate
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numerous devices susceptible to acidic environments, and that could be useful in a vast
number of applications.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Scanning electron micrographs of 5 μm cubes (1A, 1B) and 3 μm hexnut particles (1C, 1D)
fabricated using PRINT. (Scale bar: 10 μm)
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Percent rhodamine-B release verses time for 5 μm cube particles fabricated from (A) DMS,
(B) DES, and (C) DTS cross-linkers.
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Transmission electron micrographs of PRINT hexnut particles incubated in HeLa cells.
Rapidly degrading hexnut particles fabricated from the DMS crosslinker (A, scale bar: 10
μm and B–F, scale bar: 0.5 μm), and non-degrading hexnut particles fabricated from the
DTS crosslinker (G–H, scale bar: 0.5 μm).
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Confocal laser scanning micrographs of HeLa cells incubated with rapidly degrading hexnut
particles (green) and non-degrading hexnut particle (red). Micrographs highlight the phases
of particle degradation: swelling (a), fragmentation (b), and complete degradation (c). The
non-degradable particles showed no change when exposed to intracellular conditions (d)
(scale bar: 10 μm).
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Cell viability assay (CellTiter-Glo®) of hexnut particles fabricated from DMS, DES, DIS
and DTS crosslinkers. The assay was performed using HeLa (A) and SKOV3 (B).
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Figure 6. Biomedical devices fabricated from silyl ether crosslinkers
A, A silyl ether suture fabricated from DMS and rhodamine-B was degraded in media
buffered at pH 7.4 and pH 5.0 (scale bar: 1 cm). B, Silyl ether stents fabricated from
compounds 1, 2, 3 and 4 (from left to right). Each stent was placed in a medium buffered at
pH 5.0 and allowed to degrade (scale bar: 1 cm).
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Synthesis of bifunctional silyl ether (BSE) cross-linkers.
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